Double-blind, Randomized, Parallel Design, Active-controlled Phase 1 Clinical Trial to Evaluate the Efficacy and Safety of DWP712 and Botox® in Adult Patients in Need of Moderate to Severe Glabellar Lines
Latest Information Update: 10 Apr 2024
At a glance
- Drugs DWP 712 (Primary) ; Botulinum-Toxin-A
- Indications Glabellar lines
- Focus Adverse reactions
- Sponsors Daewoong Pharmaceutical
Most Recent Events
- 03 Apr 2024 Status changed from recruiting to completed.
- 29 Jan 2024 New trial record